Study of bometase alfa for bleeding control in acquired hemophilia A
This trial tests a new medicine, bometase alfa, to stop bleeding in people with a rare bleeding disorder called acquired hemophilia A. The goal is to control active bleeding episodes safely.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with acquired hemophilia A (low factor VIII and a positive inhibitor test).
- You are currently having significant bleeding, like large bruises, bleeding in the gut or bladder, or after surgery or childbirth.
- You do not have a history of blood clots, heart attack, or stroke in the last 3 months.
- You have not used certain clot-promoting medicines recently.
- You are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is studying a medication called susoctocog alfa for people with acquired hemophilia A, a bleeding disorder. It aims to understand how well the treatment works and how it is being used.
This study tests whether KN057, a new preventive medicine, is safe for males with hemophilia A or B. It aims to help prevent bleeding episodes without causing unwanted blood clots.
This trial tests a gene therapy to help your body produce more of the clotting protein (factor VIII) it's missing. It may reduce or stop the need for regular factor infusions.
This early-phase trial tests a new gene therapy called NGGT003 for men with severe hemophilia A. It aims to see if the treatment is safe and can help reduce bleeding episodes.
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
This trial tests a new drug called KN057 for people with severe hemophilia A or moderate-to-severe hemophilia B, whether or not they have developed inhibitors (antibodies that block standard treatments). The goal is to see if it can help prevent or treat bleeding episodes.
Hear when a new Acquired Hemophilia A trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.